The Malmberg lab partner in major cancer immunotherapy project
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
From major journals, first or last author from the Institute for Cancer Research
Pettersen S, Øy GF, Egeland EV, Juell S, Engebråten O, Mælandsmo GM, Prasmickaite L(2023) Breast cancer patient-derived explant cultures recapitulate in vivo drug responses Front Oncol, 13, 1040665 DOI 10.3389/fonc.2023.1040665, PubMed 36910663
Chauhan SK, Casado RB, Landsverk OJB, Johannessen H, Phung D, Nilsen HR, Sætre F, Jahnsen J, Horneland R, Yaqub S, Aandahl EM, Lundin KEA, Bækkevold ES, Jahnsen FL(2023) The human small intestine contains two functionally distinct regulatory T-cell subsets J Allergy Clin Immunol(in press) DOI 10.1016/j.jaci.2023.02.030, PubMed 36893861
Ghiasvand R, Berge LAM, Andreassen BK, Green AC, Al Rahmoun M, Fournier A, Kvaskoff M, Veierød MB, Robsahm TE(2023) Statin use and risk of cutaneous melanoma: A nationwide nested case-control study Br J Dermatol(in press) DOI 10.1093/bjd/ljad057, PubMed 36866569
Humbert M, Olofsson A, Wullimann D, Niessl J, Hodcroft EB, Cai C, Gao Y, Sohlberg E, Dyrdak R, Mikaeloff F, Neogi U, Albert J, Malmberg KJ, Lund-Johansen F, Aleman S, Björkhem-Bergman L, Jenmalm MC, Ljunggren HG, Buggert M, Karlsson AC(2023) Functional SARS-CoV-2 cross-reactive CD4+ T cells established in early childhood decline with age Proc Natl Acad Sci U S A, 120(12), e2220320120 DOI 10.1073/pnas.2220320120, PubMed 36917669
Halkola AS, Joki K, Mirtti T, Mäkelä MM, Aittokallio T, Laajala TD(2023) OSCAR: Optimal subset cardinality regression using the L0-pseudonorm with applications to prognostic modelling of prostate cancer PLoS Comput Biol, 19(3), e1010333(in press) DOI 10.1371/journal.pcbi.1010333, PubMed 36897911
Lamsal A, Andersen SB, Johansson I, Vietri M, Bokil AA, Kurganovs NJ, Rylander F, Bjørkøy G, Pettersen K, Giambelluca MS(2023) Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer Cell Commun Signal, 21(1), 50 DOI 10.1186/s12964-023-01062-y, PubMed 36882786